发布求助
文献互助 智能选刊 最新文献

Trends in cancer最新文献

筛选
英文 中文
Next-generation cancer vaccines and emerging immunotherapy combinations. 新一代癌症疫苗和新兴免疫疗法组合。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2024-08-01 Epub Date: 2024-07-23 DOI: 10.1016/j.trecan.2024.06.003
Anne Brandenburg, Annkristin Heine, Peter Brossart
{"title":"Next-generation cancer vaccines and emerging immunotherapy combinations.","authors":"Anne Brandenburg, Annkristin Heine, Peter Brossart","doi":"10.1016/j.trecan.2024.06.003","DOIUrl":"10.1016/j.trecan.2024.06.003","url":null,"abstract":"<p><p>Therapeutic cancer vaccines have been a subject of research for several decades as potential new weapons to tackle malignancies. Their goal is to induce a long-lasting and efficient antitumour-directed immune response, capable of mediating tumour regression, preventing tumour progression, and eradicating minimal residual disease, while avoiding major adverse effects. Development of new vaccine technologies and antigen prediction methods has led to significant improvements in cancer vaccine efficacy. However, for their successful clinical application, certain obstacles still need to be overcome, especially tumour-mediated immunosuppression and escape mechanisms. In this review, we introduce therapeutic cancer vaccines and subsequently discuss combination approaches of next-generation cancer vaccines and existing immunotherapies, particularly immune checkpoint inhibitors (ICIs) and adoptive cell transfer/cell-based immunotherapies.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"749-769"},"PeriodicalIF":14.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141761148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current landscape of CD3 bispecific antibodies in hematologic malignancies. 血液恶性肿瘤中 CD3 双特异性抗体的现状。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2024-08-01 Epub Date: 2024-07-10 DOI: 10.1016/j.trecan.2024.06.001
Joshua Kassner, Basma Abdellatif, Samuel Yamshon, Jorge Monge, Justin Kaner
{"title":"Current landscape of CD3 bispecific antibodies in hematologic malignancies.","authors":"Joshua Kassner, Basma Abdellatif, Samuel Yamshon, Jorge Monge, Justin Kaner","doi":"10.1016/j.trecan.2024.06.001","DOIUrl":"10.1016/j.trecan.2024.06.001","url":null,"abstract":"<p><p>Over the past 30 years the incorporation of monoclonal antibody (mAb) treatments into the management of hematologic malignancies has led to significant improvements in patient outcomes. The key limitation of mAb treatments is the necessity for target antigen presentation on major histocompatibility complex (MHC) and costimulatory molecules to elicit a cytotoxic immune response. With the advent of bispecific antibodies (BsAbs), these limitations can be overcome through direct stimulation of cytotoxic T cells, thus limiting tumor cell evasion. BsAbs are rapidly being incorporated into treatment regimens for hematologic malignancies, and there are now seven FDA-approved treatments in this class, six of which have been approved in the past year. In this review we describe the function, complications, and clinical trial data available for CD3 BsAbs in the treatment of lymphoma, myeloma, and leukemia.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"708-732"},"PeriodicalIF":14.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141580977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emerging and extensive clonal evolution in the pancreas. 胰腺新出现的广泛克隆进化。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2024-08-01 Epub Date: 2024-07-07 DOI: 10.1016/j.trecan.2024.06.011
Alvin P Makohon-Moore
{"title":"Emerging and extensive clonal evolution in the pancreas.","authors":"Alvin P Makohon-Moore","doi":"10.1016/j.trecan.2024.06.011","DOIUrl":"10.1016/j.trecan.2024.06.011","url":null,"abstract":"<p><p>Pancreatic cancer is one of the most lethal malignancies, yet much remains to be learned regarding how its precursors develop. In a recent Nature publication, Braxton and Kiemen et al. found that the normal, adult pancreas harbors hundreds to thousands of pancreatic cancer precursors evolving by a variety of routes.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"669-670"},"PeriodicalIF":14.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11415008/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141559871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reconceptualizing mental health in cancer survivorship. 重新认识癌症幸存者的心理健康。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2024-08-01 Epub Date: 2024-06-17 DOI: 10.1016/j.trecan.2024.05.008
Darren Haywood, Roman Kotov, Robert F Krueger, Aidan G C Wright, Miriam K Forbes, Evan Dauer, Frank D Baughman, Susan L Rossell, Nicolas H Hart
{"title":"Reconceptualizing mental health in cancer survivorship.","authors":"Darren Haywood, Roman Kotov, Robert F Krueger, Aidan G C Wright, Miriam K Forbes, Evan Dauer, Frank D Baughman, Susan L Rossell, Nicolas H Hart","doi":"10.1016/j.trecan.2024.05.008","DOIUrl":"10.1016/j.trecan.2024.05.008","url":null,"abstract":"<p><p>Mental health for cancer survivors in both research and clinical applications has strongly adopted a traditional nosological approach, involving the classification of psychopathology into discrete disorders. However, this approach has recently faced considerable criticism due to issues such as high comorbidity and within-disorder symptom heterogeneity across populations. Moreover, there are additional specific issues impacting the validity of traditional approaches in cancer survivorship populations, including the physiological effects of cancer and its treatments. In response, we provide the case for the hierarchical dimensional approach within psycho-oncology, in particular the Hierarchical Taxonomy of Psychopathology (HiTOP). We discuss not only the potential utility of HiTOP to research and clinical applications within psycho-oncology, but also its limitations, and what is required to apply this approach within cancer survivorship.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"677-686"},"PeriodicalIF":14.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141421123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Towards enhancing the predictive value of the microbiota for cancer immunotherapy 提高微生物群对癌症免疫疗法的预测价值
IF 18.4 1区 医学
Trends in cancer Pub Date : 2024-07-31 DOI: 10.1016/j.trecan.2024.07.007
{"title":"Towards enhancing the predictive value of the microbiota for cancer immunotherapy","authors":"","doi":"10.1016/j.trecan.2024.07.007","DOIUrl":"https://doi.org/10.1016/j.trecan.2024.07.007","url":null,"abstract":"<p>The gut microbiota has emerged as a potential determinant of immune checkpoint inhibitor (ICI) response, yet using it as a biomarker remains challenging. A recent study in <em>Cell</em> by <span><span>Derosa <em>et al.</em></span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span> describes a two-tier model based on gut microbiota composition to discriminate responder from non-responder patients with cancer, offering new ideas that could be leveraged in the clinic.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":"10 1","pages":""},"PeriodicalIF":18.4,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141862968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oncology-respirology: a discipline in dire need 肿瘤反应学：一门亟需发展的学科
IF 18.4 1区 医学
Trends in cancer Pub Date : 2024-07-26 DOI: 10.1016/j.trecan.2024.07.001
{"title":"Oncology-respirology: a discipline in dire need","authors":"","doi":"10.1016/j.trecan.2024.07.001","DOIUrl":"https://doi.org/10.1016/j.trecan.2024.07.001","url":null,"abstract":"<p>Despite the success of various cancer therapies on patient survival, these treatments can have negative side effects, particularly severe damage to the respiratory system. Given the rise in respiratory-associated illnesses in response to cancer treatment, we urge the field to consider a new discipline referred to as ‘oncology–respirology’ (or onco-respirology).</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":"14 1","pages":""},"PeriodicalIF":18.4,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141773819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advisory Board and Contents 咨询委员会和内容
IF 18.4 1区 医学
Trends in cancer Pub Date : 2024-07-09 DOI: 10.1016/s2405-8033(24)00124-9
{"title":"Advisory Board and Contents","authors":"","doi":"10.1016/s2405-8033(24)00124-9","DOIUrl":"https://doi.org/10.1016/s2405-8033(24)00124-9","url":null,"abstract":"No Abstract","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":"17 1","pages":""},"PeriodicalIF":18.4,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141577790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Subscription & copyright page 订阅和版权页面
IF 18.4 1区 医学
Trends in cancer Pub Date : 2024-07-09 DOI: 10.1016/s2405-8033(24)00127-4
{"title":"Subscription & copyright page","authors":"","doi":"10.1016/s2405-8033(24)00127-4","DOIUrl":"https://doi.org/10.1016/s2405-8033(24)00127-4","url":null,"abstract":"No Abstract","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":"27 1","pages":""},"PeriodicalIF":18.4,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141572587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COX2-dependent suppression of anticancer immunity. COX2 依赖性抑制抗癌免疫。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2024-07-01 Epub Date: 2024-05-30 DOI: 10.1016/j.trecan.2024.05.006
María Cecilia Lira, Lorenzo Galluzzi, Claire Vanpouille-Box
{"title":"COX2-dependent suppression of anticancer immunity.","authors":"María Cecilia Lira, Lorenzo Galluzzi, Claire Vanpouille-Box","doi":"10.1016/j.trecan.2024.05.006","DOIUrl":"10.1016/j.trecan.2024.05.006","url":null,"abstract":"<p><p>Prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) is well known to promote tumor progression by boosting cancer cell proliferation while inhibiting anticancer immunity. Recent data from Lacher et al. and Morotti et al. demonstrate that one of the mechanisms through which PGE<sub>2</sub> suppresses tumor-targeting immune responses involves downregulation of interleukin 2 (IL2) receptors and consequent inhibition of mitochondrial metabolism in T cells.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"573-575"},"PeriodicalIF":14.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11236508/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141184730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A new BRAF inhibitor breaks resistance barriers. 一种新型 BRAF 抑制剂打破了抗药性障碍。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2024-07-01 Epub Date: 2024-06-11 DOI: 10.1016/j.trecan.2024.05.009
Morena Scotece, Matthias Drosten
{"title":"A new BRAF inhibitor breaks resistance barriers.","authors":"Morena Scotece, Matthias Drosten","doi":"10.1016/j.trecan.2024.05.009","DOIUrl":"10.1016/j.trecan.2024.05.009","url":null,"abstract":"<p><p>Approved BRAF inhibitors have shown limited clinical benefit due to recurrent disease progression. In a recent Cancer Discovery paper, Yaeger et al. show that a next-generation BRAF inhibitor, PF-07799933, has widespread therapeutic activity in experimental models and patients who were refractory to treatment with approved BRAF inhibitors.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"576-578"},"PeriodicalIF":14.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141311839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信